Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Teva Pharmaceutical to Replace CEO Kare Schultz

Teva Pharmaceutical to Replace CEO Kare Schultz

-Wall Street Journal

byCharles Gross

November 3, 2022

1 minute read

-Wall Street Journal

Cytek Biosciences Expects Its FY23 Revenue To Be Near The High End Of The Co’s Most Recent Revenue Guidance Range Of $188M-1$192M

By Benzinga Newsdesk

January 8, 10:30 AM

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023. Cytek expects its full year revenue

CTKB

Movers
News

What’s Going On With Nikola Stock Monday?

By Adam Eckert

February 5, 10:46 AM

Nikola has opened its first HYLA hydrogen refueling station in Southern California, representing the latest phase in Nikola's commitment to providing hydrogen refueling solutions for Class 8 trucks.

NKLA

Credit Suisse Initiates Coverage On Pure Storage with Outperform Rating, Announces Price Target of $36

By Benzinga Newsdesk

August 17, 4:27 AM

Credit Suisse analyst Shannon Cross initiates coverage on Pure Storage (NYSE:PSTG) with a Outperform rating and announces Price Target of $36.

PSTG

Stephens & Co. Maintains Overweight on Mission Produce, Lowers Price Target to $15

By Benzinga Newsdesk

December 23, 9:58 AM

Stephens & Co. analyst Ben Bienvenu maintains Mission Produce (NASDAQ:AVO) with a Overweight and lowers the price target from $20 to $15.

AVO

Teva Pharmaceutical to Replace CEO Kare Schultz

Related Posts

Cytek Biosciences Expects Its FY23 Revenue To Be Near The High End Of The Co’s Most Recent Revenue Guidance Range Of $188M-1$192M

What’s Going On With Nikola Stock Monday?

Credit Suisse Initiates Coverage On Pure Storage with Outperform Rating, Announces Price Target of $36

Stephens & Co. Maintains Overweight on Mission Produce, Lowers Price Target to $15